Skip to content
Resources > Reports

State of Market Intelligence: Market Maturity Index Report

Today’s markets move at breakneck speed—generating massive amounts of information. Add in an unprecedented level of volatility and an overall increase in the pace of business, to put it lightly: gathering and acting on market intelligence has never been more challenging.

And while the pace of business has accelerated, organizations largely operate in a world full of slow decision-making. Intelligence that powers strategic decisions requires knowledge workers to be agile.

When it comes to tactically employing a sophisticated market intelligence practice, it is important to level-set and know where your company is in terms of market intelligence maturity. It is a matter of understanding where you stand without simply reacting to your competitors.

Enter: the market intelligence maturity index.

In this report, based around data from our State of Generative AI and Market Intelligence 2023survey, we delve into the challenges and costs associated with not solving them, and outline the three stages of market intelligence maturity (or lack thereof).

Explore more

Enterprise Software: Assessing AI Adoption Trends

Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
Title slide: Enterprise Software: Assessing AI Adoption Trends, by Michelle Brophy and Sean Carmichael, featuring a computer illustration and AI logo.

From Promise to Performance: How AI Will Evolve in 2026

2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
Title slide: From Promise to Performance: How AI Will Evolve in 2026 by Sarah Hoffman, Director of AI Thought Leadership, with abstract tech graphics.

Most-Favored-Nation Policy: Implications for European Drug Launches

The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.
U.S. Most-Favored-Nation Drug Pricing Policy: What Does It Mean for Europe? by Sara Mallatt and Sean Carmichael, with a stylized map of Europe.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.